Tay-Sachs Disease: Genetics, Symptoms, Progression, and Prevention

Disease Overview

Tay-Sachs is an autosomal recessive lysosomal storage disorder caused by HEXA gene mutations → deficiency of β-hexosaminidase A → accumulation of GM2 ganglioside in neurons → progressive neurodegeneration.

Classic Infantile Form

• Onset: 3–6 months (normal at birth).
• Symptoms: Hypotonia, exaggerated startle, developmental regression, cherry-red macula, seizures, blindness, deafness, dysphagia, spasticity.
• Course: Relentless progression; death typically by age 4–5.

Juvenile & Late-Onset Forms

Residual enzyme activity allows slower progression: ataxia, dystonia, psychiatric symptoms, lower motor neuron weakness; onset childhood to adulthood.

Management

• Supportive: seizure control, nutrition (GT), respiratory care, physical therapy.
• No disease-modifying therapy approved; enzyme replacement, substrate reduction, gene therapy in trials.

Prevention

• Carrier screening (enzyme assay + DNA) in high-risk populations (Ashkenazi Jewish, French Canadian, Cajun, Irish-American).
• If both partners carriers: 25% recurrence risk per pregnancy. Options: prenatal diagnosis (CVS/amnio), preimplantation genetic testing (PGT-M), donor gametes, adoption.

Genetic counseling is essential for at-risk couples.